(Q41149318)

27 September 2017

1 reference

title

Clinical pharmacokinetics of topotecan (English)

1 reference

27 September 2017

1 reference

3

J H Beijnen

1 reference

27 September 2017

W W ten Bokkel Huinink

series ordinal

2

object named as

W W ten Bokkel Huinink

1 reference

27 September 2017

V M Herben

1

1 reference

27 September 2017

publication date

1 August 1996

1 reference

Clinical Pharmacokinetics

27 September 2017

published in

1 reference

27 September 2017

volume

31

1 reference

27 September 2017

issue

2

1 reference

27 September 2017

page(s)

85-102

1 reference

Topoisomerase I and II activity in human breast, cervix, lung and colon cancer

27 September 2017

cites work

1 reference

12 December 2020

Limited sampling models for topotecan pharmacokinetics

1 reference

12 December 2020

Pharmacokinetics of reversible metabolic systems

1 reference

12 December 2020

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1 reference

12 December 2020

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

12 December 2020

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

Camptothecin effects on DNA synthesis in murine leukemia cells

1 reference

12 December 2020

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

12 December 2020

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

1 reference

12 December 2020

Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Clinical, pharmacokinetic and biological studies of topotecan.

1 reference

12 December 2020

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

1 reference

12 December 2020

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

12 December 2020

The Important Role of Albumin in Determining the Relative Human Blood Stabilities of the Camptothecin Anticancer Drugs

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Preclinical and phase I trials of topoisomerase I inhibitors

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

12 December 2020

Studies on camptothecin. I. Effects of nucleic acid and protein synthesis

1 reference

12 December 2020

A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues

1 reference

12 December 2020

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

1 reference

12 December 2020

Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy

1 reference

12 December 2020

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

12 December 2020

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

1 reference

12 December 2020

The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

12 December 2020

Preclinical and clinical development of camptothecins

1 reference

12 December 2020

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine

1 reference

12 December 2020

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

1 reference

12 December 2020

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

1 reference

12 December 2020

Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution

1 reference

12 December 2020

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

1 reference

12 December 2020

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

12 December 2020

10.2165/00003088-199631020-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

1002997980

0 references

1 reference